Phytosterols, Ezetimibe, and Cholesterol Metabolism
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but appear
to have different mechanisms of action. The investigators' hypothesis is that phytosterols
and ezetimibe given together will block cholesterol absorption in an additive fashion. In a
randomized, placebo-controlled crossover trial the effects of placebo, ezetimibe treatment
and ezetimibe plus phytosterol treatment will be measured.
Phase:
Early Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Utah State University